Dr Matthew Coleshill
PhD (Psychology)
University of Hull, United Kingdom
Bachelor of Science (Honours) in Psychology
University of Hull, United Kingdom
Dr Coleshill has a research background is in health psychology, specifically the placebo effect, treatment adherence, and the evaluation of digital health interventions. His research at the Black Dog Institute has focused on evaluating a blended care mental health support service for health professionals - The Essential Network (TEN).
Beyond this, Dr Coleshill is interested in interventions to support people experiencing burnout, interventions to reduce the experience of side effects from medications or improve medication adherence, as well as research into factors affecting patient outcomes.
- Publications
- Media
- Grants
- Awards
- Research Activities
- Engagement
- Teaching and Supervision
- Avant Foundation ($107,844 AUD), 2023. Tackling burnout in Australian doctors by blending a custom-built digital cognitive-behavioural therapy program and specialist telehealth treatment.
- Arthritis Australia Project Grant ($30,000 AUD), 2020. Effect of self-monitoring urate levels on adherence to allopurinol.
2017 Society for Interdisciplinary Placebo Studies Travel Award (€300 EUR)
2016 Ian Potter Foundation Travel Grant ($1000 AUD)
2013 Experimental Psychology Society Grindley Grant (£500 GBP)
2011 University of Hull 80th Anniversary PhD Scholarship
- Evaluation of The Essential Network (TEN). TEN is a blended care mental health support service for health professionals. This research includes both quantitative and qualitative methods examining usage of TEN, barriers to health professionals engaging with TEN, as well as formal assessment of TEN and its components through observational studies and randomised-controlled trials.
- Medication adherence in gout. This research encompasses the Gout APP (GAPP) trial, a randomised-controlled trial of a mobile application for people with gout, as well as other novel avenues for improving medication adherence in gout, such as the use of point-of-care devices.
- Medication side effects and the placebo/nocebo effects.